ProNAi Raises $12M Series C Financing To Expand Cancer StudiesThe cancer drug developer ProNAi Therapeutics Inc. Monday announced the closing of a Series C preferred financing round of more than $12 million with existing and new investors.
CytoPherx Raises $34M To Move Into U.S. Clinical TrialsCytoPherx Inc. announced it has completed a $34 million round of funding. The funds will be used to complete United States clinical trials and gain FDA approval to commercialize the CytoPherx anti-inflammatory therapy for acute kidney injury.

More From CBS Detroit

Hump Day Drinks: 8 Cheery Cocktail RecipesNow that you've made it through half the work week, it's time to celebrate!
Daily J

Watch & Listen